A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it ...
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, el...
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and sa...
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP...
Top Cities for Idiopathic Thrombocytopenic Purpura Clinical Trials
Idiopathic Thrombocytopenic Purpura clinical trials are recruiting across 31 cities. Here are the cities with the most active studies:
About Idiopathic Thrombocytopenic Purpura
Immune thrombocytopenia (ITP) is an autoimmune condition where the immune system destroys platelets, leading to easy bruising and bleeding. It can occur in children (often self-limiting) or adults (often chronic). Treatment includes corticosteroids, thrombopoietin receptor agonists, and rituximab.
Clinical trials are advancing new treatments for idiopathic thrombocytopenic purpura. Currently, 4 studies are recruiting a combined 332 participants across the United States. Research is being conducted by 4 organizations including Takeda, argenx, Eli Lilly and Company and 1 others.
2026 Idiopathic Thrombocytopenic Purpura Research Landscape
As of March 2026, the idiopathic thrombocytopenic purpura clinical trial landscape includes 4 actively recruiting studies across 31 cities in the United States. These studies are collectively seeking 332 participants, with an average enrollment target of 83 per study.
Research is being led by 4 different organizations, including Takeda, argenx, Eli Lilly and Company, Kedrion S.p.A..
Geographically, idiopathic thrombocytopenic purpura trials are most concentrated in Los Angeles, California (4 trials); Washington D.C., District of Columbia (3 trials); Iowa City, Iowa (2 trials); Greenville, North Carolina (2 trials); Philadelphia, Pennsylvania (2 trials) and 7 other cities.
Featured Idiopathic Thrombocytopenic Purpura Studies
Highlighted recruiting studies for idiopathic thrombocytopenic purpura, selected by enrollment size and research scope.
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with...
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment perio...
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check ho...
Frequently Asked Questions About Idiopathic Thrombocytopenic Purpura Clinical Trials
Are there idiopathic thrombocytopenic purpura clinical trials near me?
Yes, there are 4 idiopathic thrombocytopenic purpura clinical trials currently recruiting across 31+ cities in the United States, including Los Angeles, California; Washington D.C., District of Columbia; Iowa City, Iowa. Browse the studies above to find one at a location convenient for you.
How do I join a idiopathic thrombocytopenic purpura clinical trial?
To join a idiopathic thrombocytopenic purpura clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are idiopathic thrombocytopenic purpura clinical trials free?
Yes, participation in idiopathic thrombocytopenic purpura clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of idiopathic thrombocytopenic purpura treatments are being studied?
Current idiopathic thrombocytopenic purpura clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 4 research organizations.
Is it safe to participate in idiopathic thrombocytopenic purpura clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov